Economic & Political Weekly (EPW) August 23, 2014 Vol XlIX No 34
S Srinivasan, T Srikrishna, Malini Aisola
Despite the government’s and pharmaceutical lobby’s claims and counterclaims, the Drugs (Prices Control) Order, 2013, which covers only 18% of the total domestic market of Rs 71,246 crore, has had very little positive effect as a price control policy. This article points out that the Order leaves out much that should have been included, while including much that should have been left out. Its provisions have made the playing field more uneven, with multiple ceiling prices, which is very unfair to consumers already dealing with an irrationally priced market
Posted in Medicine, Pharma Industry, Pharma Policy, Price Control
Tagged draft policy, Drug Pricing, Generic drug, Medicine, Medicine pricing, Medicines, National Pharmaceuticals Pricing Policy, Pharma Industry, Price Control
The price caps imposed by the Indian government on 348 drugs in 2013 have created only an illusion of control, keeping many medicines for conditions ranging from asthma to diabetes and heart disease beyond price regulations… reports The Telegraph. Read more
Moneylife reports that while market-based pricing can potentially reduce the price for two-thirds of essential medicines, there are far too many loopholes. Read more
Infographic Source: The Telegraph
Mumbai: Non-government organisations (NGOs) led by AIDAN (All India Drug Action Network) have filed a fresh application in the Supreme Court as part of their decade-long petition that had forced the government to bring all 348 essential drugs under price control. AIDAN, LOCOST, Medico Friend Circle and Jan Swasthya Sahyog together have filed a fresh intervention application in the Supreme Court, opposing the National Pharmaceutical Pricing Policy (NPPP 2012) and marketbased pricing mechanism to determine ceiling prices of drugs which are being brought under price control.
According to the fresh intervention application, the simple average formula to determine the ceiling prices (of drugs) actually increases their prices and… read more
Source: Times of India
Fresh plea filed against drug price control in SC
The government’s decision to grant a compulsory licence for the manufacture of an important anti-cancer drug should be the first step towards making available essential drugs at little or no direct cost.
Read more: The Hindu, March 14, 2012
Posted in Cancer, Medicine, Patent, Pharma Industry, Pharma Policy
Tagged Drug Pricing, Generic drug, Medicine, Medicine pricing, Medicines, Patent, Pharma Industry, Pharma Policy, Price Control
“Product monopolies and high prices are back in India. The MNCs have started marketing new patented drugs at exorbitant prices particularly for life threatening diseases such as cancer…….” Read more here.
The paper “Multinationals and Monopolies: Pharmaceutical Industry in India after TRIPS” by Prof. Sudip Chaudhury from IIM Calcutta attempts to look at the MNC’s behaviour in post TRIPS scenario to show that days of product monopolies are back in India. Access this paper here